Broken String Biosciences (“Broken String”), a genomics company driving development of the next generation of more precise, safe, and effective cell and gene therapies, today announced it has appointed Steve Becker as Chief Commercial Officer. An experienced global life sciences executive, Steve will guide the expansion of the Company’s commercial operations and implement a robust go-to-market strategy for its Next-Generation Sequencing (NGS)-based DNA break-mapping platform, INDUCE-seq ® , as the Company looks to strengthen its position across key markets. Following the close of its $15M Series A funding round in 2023, Broken String has been focused on delivering an ambitious expansion strategy and revenue growth, including several high-profile leadership appointments.
Further bolstering the executive team, Steve will direct the commercialization strategy for the INDUCE-seq platform to ensure it meets the unique needs of the emerging cell and gene therapy market, including development of a scalable ‘Platform as a Service’ offering and extension of the technology’s capabilities beyond gene-editing. He will lead the global sales and marketing teams, business development function, and technical support operations, including building the Company’s US commercial operations to nurture its growing network of customers and commercial partners. Steve is a renowned leader in the industry, with over 30 years’ experience managing diverse teams to develop scalable market.